Table 3. Anticancer drugs most often prescribed to patients in the study.

INN	No. of prescriptions	Percent of prescription (%)	Need for dosage adjustment in RI	Potential nephrotoxicity
Fluorouracil	248	13.6	No	No
Zoledronate	220	12.1	Yes	Yes
Docetaxel	114	6.2	Yes	No
Cyclophosphamide	101	5.5	Yes	No
Epirubicin	94	5.2	No	SC
Trastuzumab	92	5.0	ND	SC
Gemcitabine	90	4.9	No	Yes
Cisplatin	89	4.9	Yes	Yes
Carboplatin	70	3.8	Yes	Yes
Paclitaxel	63	3.5	No	SC
Oxaliplatin	61	3.3	No	Yes
Irinotecan	53	2.9	No	Yes
Doxorubicin	52	2.8	No	SC
Capecitabin	47	2.6	Yes	No
Letrozole	42	2.3	No	No
Tamoxifen	41	2.2	No	SC
Ibandronate	35	1.9	Yes	No
Vinorelbine	32	1.8	Yes	No
Exemestane	30	1.6	No	No
Temozolomide	22	1.2	ND	No
Cetuximab	18	1.0	No	Yes
Other	238	12.9	Yes: 28.2%	Yes: 100 prescriptions
			ND: 31.5%	ND: 18 prescriptions
			No: 40.3%	No: 100 prescriptions
Total	1852	100	Yes: 41.8%	Yes: 1043 prescriptions
			ND: 10.2%	ND: 18 prescriptions
			No: 47.9%	No: 791 prescriptions

Abbreviations: INN=international non-proprietary name; ND=no data available in the literature for use in patient with RI or for nephrotoxicity; RI=renal insufficiency; SC=sparse cases.

Other: anticancer drugs that were prescribed in <1% of patients in the study (decreasing number of prescriptions): bevacizumab, gosereline, etoposide, fulvestrant, methotrexate, topotecan, anastrozole, dacarbazine, vinblastine, erlotinib, vinflunine, mitoxantrone, bicalutamide, mitomycine, megestrole, pamidronate, imatinib, ifosfamide, vaccine, bleomycin, lomustin, estramustin, fotemustin, gefitinib, leuproreline, octreotide, hydroxycarbamide, pemetrexed, triptoreline, sunitinib, panitumumab, thyrixine, cyproterone, carmustine, rituximab, streptozocine, matuzumab, sorafenib, lanreotide, ipilimumab.